Brief Treatment for Temporomandibular Pain
This study is currently recruiting patients
Verified by National Institute of Dental and Craniofacial Research (NIDCR) September 2006
| Sponsored by: |
National Institute of Dental and Craniofacial Research (NIDCR)
University of Connecticut |
| Information provided by: |
National Institute of Dental and Craniofacial Research (NIDCR) |
| ClinicalTrials.gov Identifier: |
NCT00067366 |
Purpose
Temporomandibular Disorder (TMD) is a widespread chronic pain condition. Successful psychosocial treatments for TMD have been developed, but the mechanisms by which these treatments achieve their effects are not well known. The goal of this project is to evaluate the possible mechanisms responsible for treatment gains in TMD treatment.
| Condition |
Intervention |
Phase |
Temporomandibular Joint Syndrome
Myofascial Pain Dysfunction Syndrome Temporomandibular Joint Orofacial Pain |
Behavior: Cognitive-Behavioral treatment |
Phase I Phase II
|
Study Type: Interventional Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title: Brief Focused Treatment for TMD: Mechanisms of Action
Further study details as provided by National Institute of Dental and Craniofacial Research (NIDCR):
Primary Outcomes: Pain; Pain-related interference with functioning; Depressive symptoms
Expected Total Enrollment:
116
Study start: October 2003;
Expected completion: March 2008 Last follow-up: December 2006;
Data entry closure: February 2007
TMD is a widespread chronic pain condition. Successful psychosocial treatments for TMD have been developed, but the mechanisms
by which these treatments achieve their effects are not well known. The goal of this project is to evaluate the possible mechanisms
responsible for treatment gains in TMD treatment. Men and women (N=106) with complaints of chronic facial pain for at least
3 months' duration will be recruited from the University Dental Clinics and from the community via advertisements and randomly
assigned to either a Standard Conservative Treatment (STD) employing an intraoral splint plus anti-inflammatory agents, or
to a Standard Treatment + Cognitive-Behavioral Treatment Program (STD+CBT), that will include standard treatment but also
focus on changing self-efficacy and decreasing catastrophization. Both treatments will entail 6 clinic visits. Dispositional
and situational variables derived from a comprehensive model of pain coping will be measured before and after treatment. The
situational variables, including coping responses, mood states, situational appraisals and self-efficacy, will be measured
in an experience sampling paradigm four times daily using a hand-held computer. This will be done to minimize retrospective
biases that may have hampered earlier studies of treatment process. Dependent variables will be self-report measures of distress,
pain, and interference with activities, as well as blood plasma levels of cortisol and selected cytokines, measured at the
end of the 6-week treatment period, and at follow-up points thereafter up to a 12-month follow-up. It is expected that the
STD+CBT treatment will result in measurable changes in constructs such as self-efficacy and catastrophization, and that these
changes will be related to improved outcomes compared to the STD controls. It is also expected that outcome differences between
groups will be associated with changes in inflammatory mediators (cytokine levels). Finally, it is suggested that changes
in situational treatment process variables will be associated with changes in cytokine levels. The results may indicate the
true active mechanisms of successful TMD treatment. If these mechanisms can be successfully identified it would have important
implications for the development of more effective treatment programs.
Eligibility
Ages Eligible for Study:
18 Years
-
65 Years,
Genders Eligible for Study:
Both
Criteria
Inclusion Criteria:
- Complaining of chronic TM-related pain for at least 3 months
- Positive Axis I diagnosis on the Research Diagnostic Criteria (RDC) for temporomandibular disorders (positive on at least
one Group), and may have no contraindications to TMD treatment
- Fluency in English
Exclusion Criteria:
- No previous surgery for treatment of TMD pain
- No history of rheumatoid disease
- No extensive anatomical destruction or deterioration of the TM joint
- Not diagnosed as having pain of neuropathic or odontogenic origin
- Not carrying a diagnosis of psychosis
- No current treatment for depression
- Not taking narcotic pain medication
- Not pregnant
Location
and Contact
Information
Please refer to this study by ClinicalTrials.gov identifier
NCT00067366
ConnecticutUniversity of Connecticut Health Center, Farmington,
Connecticut,
06030,
United States; Recruiting
Mark D Litt, Ph.D.
860-679-4680
Litt@nso.uchc.edu
Mark D Litt, Ph.D., Principal Investigator
Study chairs or principal investigators
Mark D Litt, Ph.D., Principal Investigator, University of Connecticut
More Information
Study ID Numbers:
NIDCR-14607
Last Updated:
September 14, 2006
Record first received:
August 15, 2003
ClinicalTrials.gov Identifier:
NCT00067366Health Authority: United States: Federal Government ClinicalTrials.gov processed this record on 2006-09-29
|